StreetInsider.com News Articles

Form SCHEDULE 13G/A IO Biotech, Inc. Filed by: HBM Healthcare Investments (Cayman) Ltd.

Mon, 06 Apr 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260406/26276538.html

Form SCHEDULE 13G/A IO Biotech, Inc. Filed by: HBM Healthcare Investments (Cayman) Ltd.

Mon, 06 Apr 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260406/26276538.html

IO Biotech files for bankruptcy and ceases operations

Tue, 31 Mar 2026 08:08:38 -0400

IO Biotech Inc. (NASDAQ: IOBT) filed for Chapter 7 bankruptcy on March 31, 2026, and ceased operations after considering strategic alternatives, according to a company filing.

The biotechnology company filed a voluntary petition for relief in the U.S. Bankruptcy Court for the District of Delaware. A Chapter 7 trustee will be appointed by the court to assume control over the company's assets and liabilities, removing authority from the board of directors and officers.

The company's assets will be liquidated and claims paid according to priorities specified in the Bankruptcy Code. The filing states that common stockholders are unlikely to receive any payment

IO Biotech files for bankruptcy and ceases operations

Tue, 31 Mar 2026 08:08:38 -0400

IO Biotech Inc. (NASDAQ: IOBT) filed for Chapter 7 bankruptcy on March 31, 2026, and ceased operations after considering strategic alternatives, according to a company filing.

The company's assets will be liquidated and claims paid according to priorities specified in the Bankruptcy Code. The filing states that common stockholders are unlikely to receive any payment

Form 8-K IO Biotech, Inc. For: Mar 31

Tue, 31 Mar 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260331/26245666.html

Form 8-K IO Biotech, Inc. For: Mar 31

Tue, 31 Mar 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260331/26245666.html

IO Biotech (IOBT) Halted, News Pending

Tue, 31 Mar 2026 07:55:24 -0400

IO Biotech (NASDAQ: IOBT) Halted, News Pending

IO Biotech (IOBT) halted, news pending

Tue, 31 Mar 2026 07:55:22 -0400

IO Biotech (IOBT) halted, news pending

Tue, 31 Mar 2026 07:55:22 -0400

IO Biotech (IOBT) halted, news pending

Form 8-K IO Biotech, Inc. For: Feb 12

Fri, 13 Feb 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260213/26002101.html

Form 8-K IO Biotech, Inc. For: Feb 12

Fri, 13 Feb 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260213/26002101.html

Form SCHEDULE 13G/A IO Biotech, Inc. Filed by: Chernett Jorey

Fri, 13 Feb 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260213/26001819.html

Form SCHEDULE 13G/A IO Biotech, Inc. Filed by: Chernett Jorey

Fri, 13 Feb 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260213/26001819.html

Form SCHEDULE 13G IO Biotech, Inc. Filed by: Point72 Asset Management, L.P.

Fri, 06 Feb 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260206/25961626.html

Form SCHEDULE 13G IO Biotech, Inc. Filed by: Point72 Asset Management, L.P.

Fri, 06 Feb 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260206/25961626.html

Form 8-K IO Biotech, Inc. For: Jan 30

Fri, 30 Jan 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260130/25924290.html

Form 8-K IO Biotech, Inc. For: Jan 30

Fri, 30 Jan 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260130/25924290.html

IO Biotech engages Raymond James, implements workforce reduction

Fri, 30 Jan 2026 08:05:23 -0400

IO Biotech Inc. (NASDAQ: IOBT) announced it has retained Raymond James & Associates Inc. as exclusive financial advisor to assist in exploring strategic alternatives, according to a company statement.

The clinical-stage biopharmaceutical company also said it is implementing cost-containment and cash conservation measures, including a significant workforce reduction, to lower operating expenses during the strategic review process.

IO Biotech develops immune-modulatory therapeutic cancer vaccines using its T-win platform technology. The company is based in Copenhagen, Denmark, with U.S. headquarters in New York.

The workforce reduction represents part of broader efforts to preserve cash while the company evaluates potential strategic options. The company had

IO Biotech Provides Corporate Update